Heptares to Present at 6th Annual BIO-Europe Spring Conference on 20 March 2012

WELWYN GARDEN CITY, England and BOSTON, March 15, 2012 /PRNewswire/ –

Heptares Therapeutics, the leading GPCR drug discovery company, announces that its
Chief Business Officer, Barry Kenny, will present overview of the Company at 09:45am CET
on Tuesday 20 March 2012 at the 6th Annual BIO-Europe Spring international partnering
conference. The presentation will take place in room E107, Level 1.

BIO-Europe Spring, which is produced by EBD Group, is taking place at the Amsterdam
RAI Convention Center in Amsterdam, the Netherlands on 19-21 March 2012.

About Heptares Therapeutics

Heptares discovers and develops new medicines targeting GPCRs (G-protein-coupled
receptors), a super-family of drug targets linked to a wide range of human diseases. We
have established R&D collaborations with Shire, Takeda, AstraZeneca, MedImmune and
Novartis Option Fund, and have raised $40M in venture financing from MVM Life Science
Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. Heptares is an
industry pioneer in GPCR structure-based drug design and has built a unique capability for
discovering novel molecules that modulate historically un-druggable or challenging GPCRs.
Our integrated discovery platform includes proprietary technologies for engineering
stabilised GPCRs in their natural pharmacological conformations, identifying previously
unknown chemistries for GPCR protein-drug interactions, and deploying advanced
fragment-based approaches to GPCR target space for the first time. Using this approach, we
are generating a broad pipeline of drug candidates for serious CNS and metabolic
disorders, including Alzheimer’s disease, Parkinson’s disease, anxiety, chronic insomnia,
addiction and diabetes. For more information, please visit http://www.heptares.com.

        Contact Information

        Citigate Dewe Rogerson
        Mark Swallow, Chris Gardner
        +44(0)20-7282-2948
        mark.swallow@citigatedr.co.uk

        Heptares Therapeutics Ltd

        Malcolm Weir, Chief Executive Officer (UK)
        +44(0)1707-358-629
        Malcolm.weir@heptares.com

        Dan Grau, President (USA)
        +1-857-222-4586
        dan.grau@heptares.com

SOURCE Heptares Therapeutics